Peptide Comparison
Lactoferricin BvsThymosin Alpha-1
A 25-amino-acid antimicrobial peptide fragment derived from bovine lactoferrin by pepsin cleavage, featuring a twisted antiparallel beta-sheet structure with broad-spectrum bactericidal activity, anti-biofilm properties, and emerging anticancer potential through selective membrane disruption mediated by the critical RRWQWR motif
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
At a Glance
Quick
comparison
Dose Range
Lactoferricin B
1–10 mg
Thymosin Alpha-1
1.6–3.2 mg
Frequency
Lactoferricin B
Multiple times daily
Thymosin Alpha-1
Twice weekly
Administration
Lactoferricin B
Oral (research — resistant to gastric digestion)
Thymosin Alpha-1
Subcutaneous injection
Cycle Length
Lactoferricin B
4-6 weeks
Thymosin Alpha-1
8-12 weeks
Onset Speed
Lactoferricin B
Rapid (hours to days)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence Level
Lactoferricin B
Moderate human trials (Phase 1-2)
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Fighting Germs
Cancer Cell Targeting
Immune Support
Immune Activation
Infection Fighting
Immune Balance
Technical Data
Compound
specifications
Lactoferricin B
Molecular Formula
Approximately C142H224N46O34S2 (varies slightly by reported sequence)
Molecular Weight
~3,126 Da (25-amino-acid bovine lactoferricin B)
Half-Life
Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance
Bioavailability
Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism
CAS Number
146897-68-9
Thymosin Alpha-1
Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
Half-Life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS Number
62304-98-7
Protocols
Dosing
tiers
Lactoferricin B
Thymosin Alpha-1
Applications
Best
suited for
Lactoferricin B
Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety Profile
Side
effects
Lactoferricin B
Common
- Mild GI discomfort
- Bitter taste
- Local irritation (topical use)
- Mild flatulence
Uncommon
- Allergic reaction in milk-sensitive individuals
Serious
- Hemolytic activity at high concentrations
Thymosin Alpha-1
Common
- Injection site reactions
- Mild fatigue
- Flu-like symptoms
Uncommon
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Lactoferricin B
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Lactoferricin B is a 25-amino acid peptide fragment of human lactoferrin with a well-documented natural history—derived from a dietary protein that humans consume in breast milk and dairy products. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations.
Contraindications
- xKnown allergy to bovine milk proteins or lactoferrin — cross-reactivity possible
- xPregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation
- xActive hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis
- xIron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule
Thymosin Alpha-1
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for other use
Safety Overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- xOrgan transplant recipients on immunosuppressants
- xActive autoimmune disease flares
- xKnown allergy to thymosin peptides
- xPregnancy or breastfeeding
- xChildren under 18 without medical supervision
Decision Guide
Which is
right for you?
Choose Lactoferricin B if...
- Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
- Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
- Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
- Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support